Natural and Synthetic Phospholipids
For Vaccines and Other Complex Drug Delivery Systems – Part 1
Übersichten
Abstract
Due to the advent and successful application of COVID-19 vaccines, based on the combined use of mRNA and Lipid Nanoparticles (LNPs), an enormous interest for (phospho)lipid carriers in vaccine research and development nowadays exists. Also other (phospho)lipid carriers such as liposomes and immune stimulating complexes (ISCOMs) are successfully used in vaccines recently introduced on the market for prophylaxis of COVID-19 and shingles, respectively. Part 1 of this article describes recent advances achieved with phospholipid-based formulations for vaccines, whereas in Part 2 phospholipid-based depot injectables and inhalation dosage forms are described.
Correspondence:
Dr. Peter Hölig, Lipoid GmbH, Frigenstr. 4, 67065 Ludwigshafen am Rhein, p.hoelig@lipoid.com
 | Dr. Peter Hölig, is a pharmacist by training. In 2022, he obtained his PhD in Pharmaceutical Technology from the University of Innsbruck, Austria. Afterwards, he joined the business development section of Lipoid GmbH where he is responsible for the scientific marketing. is a pharmacist with PhD (biochemistry, Utrecht University, NL) and degree of Privatdozent in pharmacy (University of Basel, |
